New Drug Approved for Irritable Bowel, Chronic Constipation

Linzess sanctioned for cases that don't respond to conventional treatment

THURSDAY, Aug. 30 (HealthDay News) -- Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome (IBS) accompanied by constipation, the agency said Thursday in a news release.

The National Institutes of Health estimate that some 63 million people are affected by chronic constipation, and about 15.3 million have IBS, the FDA said.

Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.

The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.

Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.

More information

Medline Plus has more about constipation.

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events